Biogen Inc - ESG Rating & Company Profile powered by AI
The report of Biogen Inc was prepared by All Street Sevva using advanced artificial intelligence. This article contains a questions and answers section about Biogen Inc. If you work at Biogen Inc and you wish to licence your Sustainability aseessment, please contact us.
Biogen Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 7.3; made up of an environmental score of 7.0, social score of 8.0 and governance score of 6.9.
7.3
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 160 | YungShin Global Holding Corp | 7.5 | High |
| 160 | Zentiva SA | 7.5 | High |
| 191 | Biogen Inc | 7.3 | High |
| 191 | Cellectis SA | 7.3 | High |
| 191 | Aurinia Pharmaceuticals Inc | 7.3 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Biogen Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Biogen Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Biogen Inc report the average age of the workforce?
Sign up for free to unlockDoes Biogen Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Biogen Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Biogen Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Biogen Inc offer flexible work?
Sign up for free to unlockDoes Biogen Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Biogen Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Biogen Inc conduct supply chain audits?
Sign up for free to unlockDoes Biogen Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Biogen Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Biogen Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Biogen Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Biogen Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Biogen Inc disclose water use targets?
Sign up for free to unlockDoes Biogen Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Biogen Inc have a product recall in the last two years?
Sign up for free to unlockDoes Biogen Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Biogen Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Biogen Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Biogen Inc disclose parental leave metrics?
Sign up for free to unlockDoes Biogen Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Biogen Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Biogen Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Biogen Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Biogen Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Biogen Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Biogen Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Biogen Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Biogen Inc disclose its waste policy?
Sign up for free to unlockDoes Biogen Inc report according to TCFD requirements?
Sign up for free to unlockDoes Biogen Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Biogen Inc disclose energy use targets?
Sign up for free to unlockDoes Biogen Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Biogen Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Biogen Inc
These potential risks are based on the size, segment and geographies of the company.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.